UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.169

Sortiert nach

Perspective: The precision-oncology illusion

Nature (London), 2016-09, Vol.537 (7619), p.S63-S63

Prasad, Vinay

2016

Link zum Volltext

Verfügbarkeit prüfen

Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval

JAMA internal medicine, 2017-11, Vol.177 (11), p.1569

2017

Link zum Volltext

Verfügbarkeit prüfen

Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?

BMC medicine, 2017-07, Vol.15 (1), p.134-134, Article 134

2017

Link zum Volltext

Verfügbarkeit prüfen

Precision oncology: origins, optimism, and potential

The lancet oncology, 2016-02, Vol.17 (2), p.e81-e86

2016

Link zum Volltext

Verfügbarkeit prüfen

Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs

Mayo Clinic proceedings, 2016-06, Vol.91 (6), p.713-725

2016

Link zum Volltext

Verfügbarkeit prüfen

The high price of anticancer drugs: origins, implications, barriers, solutions

Nature reviews. Clinical oncology, 2017-06, Vol.14 (6), p.381-390

2017

Link zum Volltext

Verfügbarkeit prüfen

Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19

Nature reviews. Clinical oncology, 2021-01, Vol.18 (1), p.7-8

2021

Link zum Volltext

Verfügbarkeit prüfen

Low-Dose Computed Tomographic Screening for Lung Cancer: Time to Implement or Unresolved Questions?

Journal of general internal medicine : JGIM, 2021-10, Vol.36 (10), p.3202-3204

2021

Link zum Volltext

Verfügbarkeit prüfen

Molecular testing to deliver personalized chemotherapy recommendations: risking over and undertreatment

BMC medicine, 2022-11, Vol.20 (1), p.1-392, Article 392

2022

Link zum Volltext

Verfügbarkeit prüfen

The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA

Translational oncology, 2022-04, Vol.18, p.101374-101374, Article 101374

2022

Link zum Volltext

Verfügbarkeit prüfen

The FDA's latest move to expand eligibility for oncology trials - a double-edged sword?

Nature reviews. Clinical oncology, 2021-12, Vol.18 (12), p.745-746

2021

Link zum Volltext

Verfügbarkeit prüfen

The precision-oncology illusion

Nature (London), 2016-09, Vol.537 (7619), p.S63

Prasad, Vinay

2016

Link zum Volltext

Verfügbarkeit prüfen

Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials

JAMA internal medicine, 2019-05, Vol.179 (5), p.642

2019

Link zum Volltext

Verfügbarkeit prüfen

An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC)

BMC cancer, 2022-01, Vol.22 (1), p.70-70, Article 70

2022

Link zum Volltext

Verfügbarkeit prüfen

Tisagenlecleucel — the first approved CAR-T-cell therapy: implications for payers and policy makers

Nature reviews. Clinical oncology, 2018-01, Vol.15 (1), p.11-12

Prasad, Vinay

2018

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant followed by adjuvant pembrolizumab in melanoma: time biases in the data analysis of the SWOG S1801 trial

Translational oncology, 2024-07, Vol.45, p.101959-101959, Article 101959

2024

Link zum Volltext

Verfügbarkeit prüfen

Comparative Effectiveness Questions in Oncology

The New England journal of medicine, 2014-04, Vol.370 (16), p.1478-1481

2014

Link zum Volltext

Verfügbarkeit prüfen

Extended anticoagulation for VTE: what evidence justifies it?

Frontiers in pharmacology, 2023-08, Vol.14, p.1241979-1241979

2023

Link zum Volltext

Verfügbarkeit prüfen

News Coverage of the American Cancer Society’s Update to Colorectal Cancer Screening Guidelines

Mayo Clinic proceedings, 2020-03, Vol.95 (3), p.617-618

2020

Link zum Volltext

Verfügbarkeit prüfen

Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines

Translational oncology, 2022-09, Vol.23, p.101475-101475, Article 101475

2022

Link zum Volltext

Verfügbarkeit prüfen

Tebentafusp in first-line melanoma trials: An outperforming outlier

Translational oncology, 2022-06, Vol.20, p.101408-101408, Article 101408

2022

Link zum Volltext

Verfügbarkeit prüfen

Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020

BMC cancer, 2023-05, Vol.23 (1), p.448-448, Article 448

2023

Link zum Volltext

Verfügbarkeit prüfen

Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm

Translational oncology, 2022-01, Vol.15 (1), p.101248-101248, Article 101248

2022

Link zum Volltext

Verfügbarkeit prüfen

A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals

eLife, 2019-06, Vol.8

2019

Link zum Volltext

Verfügbarkeit prüfen

Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer

BMC medicine, 2023-09, Vol.21 (1), p.1-344, Article 344

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.169

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(968)
Mit Volltextzugriff
(1.013)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(22)

Menü

Weitere Dienste

Einstellungen

Perspective: The precision-oncology illusion

Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval

Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?

Precision oncology: origins, optimism, and potential

Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs

The high price of anticancer drugs: origins, implications, barriers, solutions

Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19

Low-Dose Computed Tomographic Screening for Lung Cancer: Time to Implement or Unresolved Questions?

Molecular testing to deliver personalized chemotherapy recommendations: risking over and undertreatment

The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA

The FDA's latest move to expand eligibility for oncology trials - a double-edged sword?

The precision-oncology illusion

Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials

An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC)

Tisagenlecleucel — the first approved CAR-T-cell therapy: implications for payers and policy makers

Neoadjuvant followed by adjuvant pembrolizumab in melanoma: time biases in the data analysis of the SWOG S1801 trial

Comparative Effectiveness Questions in Oncology

Extended anticoagulation for VTE: what evidence justifies it?

News Coverage of the American Cancer Society’s Update to Colorectal Cancer Screening Guidelines

Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines

Tebentafusp in first-line melanoma trials: An outperforming outlier

Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020

Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm

A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals

Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer

Suchergebnisse filtern